Thesis
momentum-code follows a clean, time-tested premise: rank the 24-stock blue-chip universe by daily price momentum, buy the top positive movers, and cap individual position size to limit concentration. The universe skews toward large-cap quality — mega-cap tech (AAPL, MSFT, NVDA, GOOGL), financials (JPM, BAC, V, MA), and defensive consumer names (PG, KO, WMT) — so the strategy operates with a built-in quality filter rather than chasing speculative names.
Cross-Validation Performance
The four-fold walk-forward results are the most encouraging feature of this strategy.
| Fold | Period | Return | Sharpe | Max DD |
|---|---|---|---|---|
| 1 | Aug 2024 – Jan 2025 | +15.38% | 2.47 | 6.12% |
| 2 | Jan 2025 – Jul 2025 | +3.27% | 0.46 | 16.55% |
| 3 | Jul 2025 – Dec 2025 | +12.18% | 2.31 | 5.21% |
| 4 | Dec 2025 – May 2026 | +13.71% | 1.93 | 6.32% |
All four folds are positive — a meaningful signal with only five trades per fold. The out-of-sample period (Fold 4) produced the strategy's best risk-adjusted result, a Sharpe of 1.93 on a 13.71% return with a contained 6.32% drawdown. That consistency across time periods is a genuine strength.
Fold 2 stands out as the stress period: a volatile first half of 2025 pushed drawdown to 16.55% and compressed the Sharpe to 0.46. The recovery in Folds 3 and 4 suggests the strategy's edge reasserts itself once momentum signals clarify after a choppy regime.
Validation Status: Not Yet Passing
Despite the clean fold results, momentum-code has not cleared the validation gate. The culprit is the Deflated Sharpe Ratio (DSR) at 0.338 — well below the threshold that corrects for multiple-testing bias across the six parameter trials evaluated. The Probabilistic Sharpe Ratio (PSR) of 0.811 is more encouraging and suggests the full-sample Sharpe of 0.65 is likely real, but PSR alone is insufficient when a strategy has been iterated across multiple configurations.
In plain terms: the strategy shows genuine edge, but the validation framework cannot yet rule out that some of the observed performance is a product of trial-and-error selection rather than a durable alpha source. Reducing the number of parameter variants tested — or accumulating more live trades — is the cleaner path to a DSR above threshold.
Recent Activity: Selective and Quiet
The last five executed trades all landed on May 31 – June 1: buys in MSFT, HON, BAC, NVDA, and XOM. Since then, every scheduled run has produced zero executions.
From June 17 through June 24, the strategy rejected between one and three signals per session while portfolio value drifted between $9,448 and $9,620 against a cash reserve of $608.79. This signals that current movers are not clearing the positive-momentum threshold or the position-cap constraint — not a malfunction, but an extended dry spell that puts the five-trade backtest count into sharper relief.
Risks to Watch
- Thin trade history: five total executions is a very small sample. Fold-level Sharpe ratios carry wide confidence intervals at this count.
- Maximum drawdown at 20.48%: the full-backtest drawdown nearly triples what any single fold experienced, suggesting intra-fold timing matters more than fold averages convey.
- High turnover: 92.74% annual turnover means the strategy would be fee-sensitive at scale, though paper-trading fees total just $5 across the backtest window.
- Quiet regime dependency: three-plus weeks of rejections hint that momentum-code may underperform in low-dispersion markets where no single name stands out.
Bottom Line
momentum-code has a coherent thesis and an honest cross-validation track record — four for four positive folds is not nothing. The validation flag is a process guardrail, not a verdict on the underlying idea. The next milestone is straightforward: more live run data to close the gap between PSR and DSR. Worth watching, not yet worth deploying capital against.